New hope for hard-to-treat leukemia: triple drug combo enters human testing
NCT ID NCT07133997
First seen Jun 27, 2026 · Last updated Jul 15, 2026 · Updated 2 times
Summary
This early-phase trial tests whether combining three drugs (recombinant Erwinia asparaginase, venetoclax, and blinatumomab) is safe and effective for adults whose B-cell acute lymphoblastic leukemia has returned or not responded to prior treatment. The study enrolls 26 people aged 12 to 55. Researchers will monitor side effects and look for signs that the cancer goes into remission.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT B ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
City of Hope Medical Center
RECRUITINGDuarte, California, 91010, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can engineered immune cells outsmart resistant blood cancers?
- Triple-Target CAR T-Cells offer new hope for tough blood cancers
- New drug cocktail shows promise for Hard-to-Treat leukemia
- Can a pill make CAR T-Cell therapy last longer?
- Smart drug hunts down hidden leukemia cells
- New cocktail of cancer drugs shows promise in early leukemia trial